Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDGFRB | P09619 | 4/20 | 0.76 |
| ▸ | PLK4 | O00444 | 2/20 | 0.76 |
| ▸ | PLK1 | P53350 | 2/20 | 0.76 |
| ▸ | RET | P07949 | 1/20 | 0.76 |
| ▸ | FLT3 | P36888 | 1/20 | 0.76 |
| ▸ | KDR | P35968 | 1/20 | 0.76 |
| ▸ | PIM1 | P11309 | 1/20 | 0.74 |
| ▸ | MAPT | P10636 | 6/20 | 0.69 |
| ▸ | APP | P05067 | 5/20 | 0.69 |
| ▸ | SNCA | P37840 | 5/20 | 0.69 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.69 |
| ▸ | MEN1 | O00255 | 2/20 | 0.69 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.69 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.69 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.69 |
| ▸ | CTRC | Q99895 | 2/20 | 0.69 |
| ▸ | NPC1 | O15118 | 1/20 | 0.69 |
| ▸ | GMNN | O75496 | 1/20 | 0.69 |
| ▸ | LMNA | P02545 | 1/20 | 0.69 |
| ▸ | HPGD | P15428 | 1/20 | 0.69 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29875506 | 1.00 | PDGFRB (0.76) | PDGFRBPLK4PLK1RETFLT3 | |
| SCHEMBL247891 | 1.00 | PDGFRB (0.76) | PDGFRBPLK4PLK1RETFLT3 | |
| SCHEMBL247890 | 1.00 | PDGFRB (0.76) | PDGFRBPLK4PLK1RETFLT3 | |
| SCHEMBL16442340 | 0.90 | PDGFRB (0.72) | PDGFRBPLK4PLK1RETFLT3 | |
| SCHEMBL16442341 | 0.86 | PDGFRB (1.00) | PDGFRBPLK4PLK1RETFLT3 | |
| SCHEMBL5475546 | 0.86 | KDR (1.00) | PDGFRBPLK4PLK1RETFLT3 | |
| SCHEMBL5319070 | 0.86 | MAPT (0.71) | PDGFRBPLK4PLK1RETFLT3 | |
| SCHEMBL5470603 | 0.86 | PDGFRB (1.00) | PDGFRBPLK4PLK1RETFLT3 | |
| SCHEMBL5481962 | 0.86 | PDGFRB (0.72) | PDGFRBPLK4PLK1RETFLT3 | |
| SCHEMBL3284695 | 0.86 | FLT3 (0.66) | PDGFRBPLK4PLK1RETFLT3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 129 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024047248-A1 | USE OF NRF2 ACTIVATORS FOR THE TREATMENT OF CEREBRAL SMALL VESSEL DISEASE | Institut National de la Santé et de la Recherche Médicale (FR) | 2024-03-07 | — | — | WO | claimed |
| US-20210069159-A1 | Bach1 Inhibitors in Combination with Nrf2 Activators and Pharmaceutical Compositions Thereof | VTV THERAPEUTICS LLC | 2021-03-11 | — | — | US | claimed |
| US-10898475-B2 | Bach1 inhibitors in combination with Nrf2 activators and pharmaceutical compositions thereof | VTV THERAPEUTICS LLC (US) | 2021-01-26 | — | — | US | claimed |
| US-10450295-B2 | Method of using an indolinone molecule and derivatives for inhibiting liver fibrosis and hepatitis | Acclaim BioMed USA LLC (US) | 2019-10-22 | — | — | US | claimed |
| US-20170231967-A1 | Bach1 Inhibitors in Combination with Nrf2 Activators and Pharmaceutical Compositions Thereof | VTV THERAPEUTICS LLC | 2017-08-17 | — | — | US | claimed |
| WO-2016089648-A1 | BACH 1 INHIBITORS IN COMBINATION WITH NRF2 ACTIVATORS AND PHARMACEUTICAL COMPOSITIONS THEREOF | VTV THERAPEUTICS LLC (US) | 2016-06-09 | — | — | WO | claimed |
| US-20150374694-A1 | TGF-BETA ENHANCING COMPOSITIONS FOR CARTILAGE REPAIR AND METHODS RELATED THERETO | THE UNITED STATES GOVERNMENT AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS | 2015-12-31 | — | — | US | claimed |
| US-20150045395-A1 | METHOD OF USING AN INDOLINONE MOLECULE AND DERIVATIVES FOR INHIBITING LIVER FIBROSIS AND HEPATITIS | Acclaim BioMed USA LLC (US) | 2015-02-12 | — | — | US | claimed |
| WO-2014130411-A9 | TGF-BETA ENHANCING COMPOSITIONS FOR CARTILAGE REPAIR AND METHODS RELATED THERETO | EMORY UNIVERSITY (US) | 2014-10-16 | — | — | WO | claimed |
| WO-2014130411-A1 | TGF-BETA ENHANCING COMPOSITIONS FOR CARTILAGE REPAIR AND METHODS RELATED THERETO | EMORY UNIVERSITY (US) | 2014-08-28 | — | — | WO | claimed |
| US-20130344165-A1 | JAB1 INHIBITORY COMPOSITIONS FOR OSSIFICATION AND METHODS RELATED THERETO | EMORY UNIVERSITY (US) | 2013-12-26 | — | — | US | claimed |
| WO-2012116137-A2 | JAB1 BLOCKING COMPOSITIONS FOR OSSIFICATION AND METHODS RELATED THERETO | EMORY UNIVERSITY (US) | 2012-08-30 | — | — | WO | claimed |
| US-20070167488-A1 | Novel therapeutic use | LEO PHARMA A/S (DK) | 2007-07-19 | — | — | US | claimed |
| US-5880141-A | CONTROLLING, MODULATING AND INHIBITING TYROSINE KINASE SIGNAL TRANSDUCTION | SUGEN, INC. (US) | 1999-03-09 | — | — | US | claimed |
| US-12377194-B2 | JAB1 inhibitory compositions for ossification and methods related thereto | EMORY UNIVERSITY (US) | 2025-08-05 | — | — | US | disclosed |
| WO-2024047248-A1 | USE OF NRF2 ACTIVATORS FOR THE TREATMENT OF CEREBRAL SMALL VESSEL DISEASE | Institut National de la Santé et de la Recherche Médicale (FR) | 2024-03-07 | — | — | WO | disclosed |
| US-20230190720-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING GLITAZONES AND NRF2 ACTIVATORS | KAHRS, Bjoern Colin (CH) | 2023-06-22 | — | — | US | disclosed |
| US-5792783-A | CAPABLE OF MODULATING TYROSINE KINASE SIGNAL TRANSDUCTION IN ORDER TO REGULATE, MODULATE AND/OR INHIBIT ABNORMAL CELL PROLIFERATION | SUGEN, INC. (US) | 1998-08-11 | — | — | US | disclosed |
| EP-0769947-A1 | INDOLINONE COMPOUNDS FOR THE TREATMENT OF DISEASE | Sugen, Inc. (US) | 1997-05-02 | — | — | EP | disclosed |
| WO-1996040116-A1 | INDOLINONE COMPOUNDS FOR THE TREATMENT OF DISEASE | SUGEN, INC. (US) | 1996-12-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150045395-A1 | METHOD OF USING AN INDOLINONE MOLECULE AND DERIVATIVES FOR INHIBITING LIVER FIBROSIS AND HEPATITIS | MMP1, HES1, COLGALT1 | PDGFRB 1393/4885PLK4 3130/4885PLK1 2575/4885 |
| US-20170231967-A1 | Bach1 Inhibitors in Combination with Nrf2 Activators and Pharmaceutical Compositions Thereof | BACH1, KEAP1, NFE2L2 | PDGFRB 3605/4885PLK4 2915/4885PLK1 587/4885 |
| US-20150374694-A1 | TGF-BETA ENHANCING COMPOSITIONS FOR CARTILAGE REPAIR AND METHODS RELATED THERETO | COL2A1, TGFB1, TGFBR1 | PDGFRB 29/4885PLK4 3846/4885PLK1 1087/4885 |
| US-10898475-B2 | Bach1 inhibitors in combination with Nrf2 activators and pharmaceutical compositions thereof | BACH1, KEAP1, NFE2L2 | PDGFRB 3060/4885PLK4 3457/4885PLK1 1159/4885 |
| US-20210069159-A1 | Bach1 Inhibitors in Combination with Nrf2 Activators and Pharmaceutical Compositions Thereof | BACH1, KEAP1, NFE2L2 | PDGFRB 3069/4885PLK4 3305/4885PLK1 767/4885 |
| US-20070167488-A1 | Novel therapeutic use | MAG, PMP22, MYT1 | PDGFRB 4421/4885PLK4 3502/4885PLK1 1202/4885 |
| US-10450295-B2 | Method of using an indolinone molecule and derivatives for inhibiting liver fibrosis and hepatitis | MMP1, HES1, COLGALT1 | PDGFRB 1393/4885PLK4 3130/4885PLK1 2575/4885 |
| US-20230190720-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING GLITAZONES AND NRF2 ACTIVATORS | PPARG, PPARA, PPARD | PDGFRB 725/4885PLK4 1206/4885PLK1 2458/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.